The Journey of Morphine

Morphine is a naturally occurring phenanthrene alkaloid with a
pKa of 7.9. At physiological pH, roughly 23% is un-ionized (lipid-soluble form) while 77% is
ionized. Its moderate lipophilicity (logP 0.89) and active transport processes allow absorption
from the GI tract, but bioavailability after oral administration is highly variable (15-60%, mean
~25%) due to extensive first-pass hepatic glucuronidation and pre-systemic sulfation in the gut
wall. Peak plasma concentrations occur 30-90 minutes after oral immediate-release tablets. Sustained-
release oral formulations (MS Contin) maintain therapeutic levels for 8-12 hours. Parenteral
routes (IV, IM, SC) bypass first-pass metabolism and provide nearly complete bioavailability
but require titration due to rapid peak effects. Intranasal and sublingual administration offers
intermediate bioavailability. Morphine sulfate and morphine hydrochloride salts are used clinically.

Morphine distributes widely but unevenly. Plasma protein binding
is relatively modest (30-35%), primarily to albumin and immunoglobulins. Volume of distribution
is large (1-4.7 L/kg), reflecting extensive tissue sequestration. Despite its modest lipophilicity,
morphine crosses the blood-brain barrier and accumulates in the CNS, though more slowly than highly
lipophilic opioids like fentanyl. Brain concentrations peak 15-30 minutes after IV dosing. Morphine
also concentrates in kidney, liver, lung, and skeletal muscle. It readily crosses the placenta and
can cause neonatal respiratory depression. Morphine-6-glucuronide (M6G), the active metabolite,
accumulates in the CNS with continued dosing and becomes more important clinically with extended use,
particularly in renal failure where it accumulates to toxic levels.

Morphine activates mu-opioid receptors (MOR, OPRM1), Gi/o-coupled
GPCRs expressed in the periaqueductal gray (PAG), dorsal horn of the spinal cord (substantia
gelatinosa), thalamic nuclei, limbic system, and peripheral sensory neurons. Receptor activation
causes: (1) inhibition of adenylyl cyclase, reducing cAMP; (2) opening of inwardly rectifying
K+ channels (GIRK), causing hyperpolarization; (3) inhibition of voltage-gated Ca²⁺ channels,
reducing neurotransmitter release from presynaptic terminals. Net result: decreased pain signal
transmission at spinal and supraspinal levels, altered pain affect in limbic circuits (emotional
component), and inhibition of ascending pain pathways via disinhibition (PAG-mediated descending
inhibitory pathways to the dorsal horn). Respiratory depression occurs because MORs in the pre-
Botzinger complex (rhythmic breathing generator) reduce CO₂-sensitive neuronal firing. Euphoria
arises from mesolimbic VTA-nucleus accumbens dopamine release. With continued exposure, receptor
desensitization (via GRK-arrestin internalization) and downregulation cause tolerance.

Morphine is metabolized primarily in the liver (and intestinal
wall) by UDP-glucuronosyltransferases — principally UGT2B7 — via direct glucuronidation at the
3-OH and 6-OH positions. Morphine-3-glucuronide (M3G) is the predominant metabolite (~50-60%)
and is pharmacologically inactive but may be neuro-excitatory at high concentrations (possibly
contributing to opioid-induced hyperalgesia and allodynia). Morphine-6-glucuronide (M6G,
~10-15%) is an active metabolite equipotent to morphine at the mu-opioid receptor, with a longer
half-life and substantial CNS penetration with repeated dosing. N-demethylation by CYP3A4 produces
normorphine (a minor pathway). Sulfation at the 3-OH position occurs in the gut wall and
contributes to first-pass extraction.

Morphine and its glucuronide metabolites are primarily excreted
by the kidneys. M3G and M6G are excreted by glomerular filtration and active tubular secretion
via organic anion transporters. In renal impairment, M6G accumulates dramatically — patients
with ESRD can develop profound and prolonged opioid toxicity from accumulating active metabolite.
The plasma half-life of morphine is 2-3 hours (immediate-release), but the effective analgesic
duration is 4-6 hours partly due to M6G accumulation. About 90% of a dose is recovered in urine
within 24-48 hours (predominantly as glucuronide conjugates), with about 7-10% in feces via
enterohepatic recirculation.

Morphine is the reference opioid analgesic for moderate to severe
pain, cancer pain management, and acute pulmonary edema. Oral morphine equivalents (OME) are the
standard for opioid dose conversion. Key safety concerns include respiratory depression (reversed
by naloxone), constipation (tolerance does not develop — peripheral MOR), nausea/vomiting
(area postrema), and dependence/addiction. Renal impairment necessitates dose reduction and
interval extension due to M6G accumulation. Serotonin syndrome risk exists with concomitant
serotoninergic drugs due to tramadol-morphine combinations.